Teva-Handok acquires approval of ‘CINQAIR,’ biologic for treatment of severe asthma patients

Published: 2017-09-08 10:15:26

Updated: 2017-09-08 10:15:26

Teva-Handok(CEO Sun-Dong Park) announced that ‘CINQAIR(generic name: reslizumab),’ a new monoclonal antibody injection for the treatment of asthma, acquired approval from the Ministry of Food and Drug Safety on the 4th.

CINQAIR is a monoclonal antibody(IgG4 kappa) targeting interleukin-5, a cytokine that is responsible for the maturation, survival and release of eosinophils, which inhibits an...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.